BiotechTube

DISC-1459 + DISC-1459 + Placebo

Phase 2Completed
0 watching 0 views this week⚡ Active
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Erythropoietic Protoporphyria

Conditions

Erythropoietic Protoporphyria

Trial Timeline

Oct 31, 2022 → Aug 23, 2024

NCT ID
NCT05308472

About DISC-1459 + DISC-1459 + Placebo

DISC-1459 + DISC-1459 + Placebo is a phase 2 stage product being developed by Disc Medicine for Erythropoietic Protoporphyria. The current trial status is completed. This product is registered under clinical trial identifier NCT05308472. Target conditions include Erythropoietic Protoporphyria.

Hype Score Breakdown

Clinical
17
Activity
12
Company
5
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT05308472Phase 2Completed

Competing Products

8 competing products in Erythropoietic Protoporphyria

See all competitors
ProductCompanyStageHype Score
Placebo + DISC-1459Disc MedicinePhase 3
72
DISC-1459 + DISC-1459Disc MedicinePhase 2/3
60
AfamelanotideClinuvel PharmaceuticalsPhase 3
69
Afamelanotide + PlaceboClinuvel PharmaceuticalsPhase 3
69
Afamelanotide 16mg implantClinuvel PharmaceuticalsPhase 1/2
33
Afamelanotide + PlaceboClinuvel PharmaceuticalsPhase 3
69
Afamelanotide + PlaceboClinuvel PharmaceuticalsPhase 2
44
Afamelanotide + PlaceboClinuvel PharmaceuticalsPhase 3
69

Other Products from Disc Medicine

Placebo + DISC-1459Phase 3
72
DISC-1459 + DISC-1459Phase 2/3
60
DISC-0974 + PlaceboPhase 2
47
DISC-3405Phase 2
47
DISC-0974Phase 1/2
36